PRME vs. CRBP

Last updated Apr 1, 2026

Compare and contrast key facts about Prime Medicine Inc. Common Stock (PRME) and Corbus Pharmaceuticals Holdings, Inc. (CRBP).

Performance

PRME vs. CRBP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Prime Medicine Inc. Common Stock (PRME) and Corbus Pharmaceuticals Holdings, Inc. (CRBP). The values are adjusted to include any dividend payments, if applicable.

PRME vs. CRBP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
PRME Prime Medicine Inc. Common Stock	0.29%	18.84%	-67.04%	-52.31%	20.88%
CRBP Corbus Pharmaceuticals Holdings, Inc.	15.36%	-31.02%	95.36%	82.20%	-17.84%

Fundamentals

Market Cap PRME : $517.68M CRBP : $125.05M
EPS PRME : -$1.38 CRBP : -$6.22
PB Ratio PRME : 4.28 CRBP : 0.85
Total Revenue (TTM) PRME : $4.63M CRBP : $0.00
Gross Profit (TTM) PRME : $0.00 CRBP : $0.00
EBITDA (TTM) PRME : -$195.76M CRBP : $0.00

Returns By Period

In the year-to-date period, PRME achieves a 0.29% return, which is significantly lower than CRBP's 15.36% return.

PRME

• 1D: 10.48%
• 1M: -24.68%
• YTD: 0.29%
• 6M: -37.18%
• 1Y: 74.87%
• 3Y*: -34.35%
• 5Y*: —
• 10Y*: —

CRBP

• 1D: 9.19%
• 1M: 9.57%
• YTD: 15.36%
• 6M: -25.77%
• 1Y: 76.84%
• 3Y*: 8.90%
• 5Y*: -31.33%
• 10Y*: -16.05%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

PRME vs. CRBP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PRME

PRME Risk / Return Rank: 68
PRME Sharpe Ratio Rank: 65
PRME Sortino Ratio Rank: 74
PRME Omega Ratio Rank: 66
PRME Calmar Ratio Rank: 70
PRME Martin Ratio Rank: 63

CRBP

CRBP Risk / Return Rank: 69
CRBP Sharpe Ratio Rank: 75
CRBP Sortino Ratio Rank: 73
CRBP Omega Ratio Rank: 72
CRBP Calmar Ratio Rank: 66
CRBP Martin Ratio Rank: 61

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PRME vs. CRBP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Prime Medicine Inc. Common Stock (PRME) and Corbus Pharmaceuticals Holdings, Inc. (CRBP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	PRME	CRBP	Difference
Sharpe ratio Return per unit of total volatility	0.67	0.99	-0.32
Sortino ratio Return per unit of downside risk	1.78	1.72	+0.06
Omega ratio Gain probability vs. loss probability	1.19	1.22	-0.04
Calmar ratio Return relative to maximum drawdown	1.42	1.13	+0.28
Martin ratio Return relative to average drawdown	2.29	2.02	+0.27
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

PRME vs. CRBP - Sharpe Ratio Comparison

The current PRME Sharpe Ratio is 0.67, which is lower than the CRBP Sharpe Ratio of 0.99. The chart below compares the historical Sharpe Ratios of PRME and CRBP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	PRME	CRBP	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.67	0.99	-0.32
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.20	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.12	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.39	-0.14	-0.25

Correlation

The correlation between PRME and CRBP is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

PRME vs. CRBP - Dividend Comparison

Neither PRME nor CRBP has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

PRME vs. CRBP - Drawdown Comparison

The maximum PRME drawdown since its inception was -94.55%, roughly equal to the maximum CRBP drawdown of -99.31%. Use the drawdown chart below to compare losses from any high point for PRME and CRBP.

Drawdown Indicators

	PRME	CRBP	Difference
Max Drawdown Largest peak-to-trough decline	-94.55%	-99.31%	+4.76%
Max Drawdown (1Y) Largest decline over 1 year	-52.77%	-61.83%	+9.06%
Max Drawdown (5Y) Largest decline over 5 years	—	-96.77%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-99.31%	—
Current Drawdown Current decline from peak	-83.52%	-96.98%	+13.46%
Average Drawdown Average peak-to-trough decline	-64.37%	-65.53%	+1.16%
Ulcer Index Depth and duration of drawdowns from previous peaks	32.70%	34.70%	-2.00%

Volatility

PRME vs. CRBP - Volatility Comparison

The current volatility for Prime Medicine Inc. Common Stock (PRME) is 21.00%, while Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a volatility of 28.04%. This indicates that PRME experiences smaller price fluctuations and is considered to be less risky than CRBP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PRME	CRBP	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.00%	28.04%	-7.04%
Volatility (6M) Calculated over the trailing 6-month period	66.76%	59.77%	+6.99%
Volatility (1Y) Calculated over the trailing 1-year period	112.28%	78.34%	+33.94%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	91.01%	158.79%	-67.78%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	91.01%	128.85%	-37.84%

Financials